...
BBOTSMALL

BridgeBio Oncology Therapeutics Inc.

HealthcareBiotechnology
$10.03
$0.00(-2.15%)
52W$8.50
$14.87
FinancialsValuationvs RVMD
Updated Mar 2, 12:00 AM
RSI41
RS Rating36/99
Beta0.26
Volatility60%
F-Score4/9
Mkt Cap$794M
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

BridgeBio Oncology Therapeutics Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 36), showing significant lag compared to the market leaders. Earnings contraction of 20% provides fundamental context to the price action. Investors should exercise caution due to high volatility (60% annualized), which requires wider risk management.

Relative Strength
36
out of 99
Lagging
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
0.26
vs S&P 500
LOW VOL
52W Position
24%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$11.67
50 SMA > 100 SMA$11.88
100 SMA > 150 SMA$11.41
150 SMA > 200 SMA$11.25

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$10.88-7.78%BELOW
50 SMA$11.67-14.04%BELOW
100 SMA$11.88-15.55%BELOW
150 SMA$11.41-12.09%BELOW
200 SMA$11.25-10.82%BELOW

Price Performance

1D-2.1%
1W-1.2%
1M-22.7%
3M-18.5%
6M+6.1%
YTD-18.4%
1Y-9.2%
3Y-0.5%
52-Week Trading Range24% from low
$10.03
52W Low$8.50
52W High$14.87

Technical Indicators

RSI (14)NEUTRAL
40.7
305070
VCP ScoreCOOL
5/10
Base depth: 50.3%

Risk Profile

Beta
0.26
52W Vol
60%
ATR
$0.64
Max DD (1Y)
-27%

Volume Analysis

Today
10
50D Avg
267.3K
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24+6100%
$0.12
Q1'25-140%
$-0.02
Q2'25-57%
$0.04
Q3'25-2000%
$-1.90
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:—
3 Years:—
TTM:—

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-8.40%

Stock Price CAGR

10 Years:-0.16%
5 Years:-0.32%
3 Years:-0.53%
1 Year:-9.23%

Return on Equity

10Y Avg:-78.7%
5Y Avg:-78.7%
3Y Avg:-78.7%
Last Year:-25.7%

Key Metrics

Market Cap$794M
Gross Margin—
Net Margin—
Piotroski F-Score4/9

More BBOT Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

BBOT vs RVMDRVMDINCYGMABEXEL

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 36 meansBBOT outperformed 36% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.26 means 74% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 4/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is BBOT in an uptrend right now?

BBOT has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is BBOT overbought or oversold?

BBOT's RSI (14) is 41. The stock is in neutral territory, neither overbought nor oversold.

Is BBOT outperforming the market?

BBOT has a Relative Strength (RS) Rating of 36 out of 99. BBOT is currently lagging the broader market.

Where is BBOT in its 52-week range?

BBOT is trading at $10.03, which is 67% of its 52-week high ($14.87) and 24% above its 52-week low ($8.50).

How volatile is BBOT?

BBOT has a Beta of 0.26 and 52-week volatility of 60%. It's less volatile than the S&P 500 - generally more stable.